Triazine containing anionic compounds useful as antiviral agents
AssigneeAmerican Cyanamid Company
InventorsYakov Gluzman, deceased, James P. LaRocque, Bryan M. O'Hara, John E. Morin, George A. Ellestad, Boris Mitsner, Wei-Dong Ding, Yuri E. Raifeld, Antonina A. Nikitenko
Life of this patent
Estimating the term…
Abstract
This invention provides triazine ring containing anionic compounds, pharmaceutical compositions containing these compounds and methods utilizing these compounds for treating viral infections, particularly infections by respiratory syncitial virus, the compounds having the general structure: ##STR1## and the pharmaceutically acceptable salt thereof.
Claims39
A compound having the structure:
- ##STR16## wherein:
- A is a moiety selected from the group consisting of ##STR17## C' is selected from --SO.sub.3 H, --OSO.sub.3 H, --OH, or --COOH;
- B' is selected from --NH, --NR.sup.1 or O;
- R.sup.1 is selected from H, (C.sub.1 -C.sub.6)lower alkyl straight or branched wherein the carbon atoms may be optionally substituted with Cl, Br, F, OH or CN;
- X is selected from Cl, F or the moiety ##STR18## where U' is selected from the group of --SO.sub.2, --CO, --NC(O), or --NC(S);
- W' is selected from the moieties:
- ##STR19## Y is --(CH.sub.2).sub.n --;
- n is 0 to 6;
- m is 0 to 2;
- Z is selected from H, CH.sub.3, CF.sub.3, --CH.sub.2 --(halogen), where halogen is Cl, Br, F or I, --CH.sub.2 OH, --COOH, --COO(C.sub.1 -C.sub.6)lower alkyl straight or branched, --CONR.sup.2 R.sup.2, CN or ##STR20## R.sup.2, in each occurrence, is independently selected from H or (C.sub.1 -C.sub.6)lower alkyl;
- or a pharmaceutically acceptable salt or ester thereof.
A method for treating a respiratory syncytial viral infection in a mammal, the method comprising administering to the mammal experiencing the respiratory syncytial viral infection an efficacious amount of a compound of the structure:
- ##STR27## wherein:
- A is a moiety selected from the group consisting of ##STR28## C' is selected from --SO.sub.3 H, --OSO.sub.3 H, --OH, or --COOH;
- B' is selected from --NH, --NR.sup.1 or O;
- R.sup.1 is selected from H, (C.sub.1 -C.sub.6)lower alkyl straight or branched wherein the carbon atoms may be optionally substituted with Cl, Br, F, OH or CN;
- X is selected from Cl, F or the moiety ##STR29## where U' is selected from the group of --SO.sub.2, --CO, --NC(O), or --NC(S);
- W' is selected from the moieties:
- ##STR30## Y is --(CH.sub.2).sub.n --;
- n is 0 to 6;
- m is 0 to 2;
- Z is selected from H, CH.sub.3, CF.sub.3, --CH.sub.2 --(halogen), where halogen is Cl, Br, F or I, --CH.sub.2 OH, --COOH, --COO(C.sub.1 -C.sub.6)lower alkyl straight or branched, --CONR.sup.2 R.sup.2, CN or ##STR31## R.sup.2 is independently selected from H or (C.sub.1 -C.sub.6)lower alkyl;
- or a pharmaceutically acceptable salt or ester thereof.
A pharmaceutical composition comprising a compound of the structure:
- ##STR32## wherein:
- A is a moiety selected from the group consisting of ##STR33## C' is selected from --SO.sub.3 H, --OSO.sub.3 H, --OH, or --COOH;
- B' is selected from --NH, --NR.sup.1 or O;
- R.sup.1 is selected from H, (C.sub.1 -C.sub.6)lower alkyl straight or branched wherein the carbon atoms may be optionally substituted with Cl, Br, F, OH or CN;
- X is selected from Cl, F or the moiety ##STR34## where U' is selected from the group of --SO.sub.2, --CO, --NC(O), or --NC(S);
- W' is selected from the moieties:
- ##STR35## Y is --(CH.sub.2).sub.n --;
- n is 0 to 6;
- m is 0 to 2;
- Z is selected from H, CH.sub.3, CF.sub.3, --CH.sub.2 --(halogen), where halogen is Cl, Br, F or I, --CH.sub.2 OH, --COOH, --COO(C.sub.1 -C.sub.6)lower alkyl straight or branched, --CONR.sup.2 R.sup.2, CN or ##STR36## and R.sup.2 is independently selected from H or (C.sub.1 -C.sub.6)lower alkyl;
- or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable carriers or excipients.
Dependencies are inferred from the claim text.